Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth policy | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFidelis Care | Wellcare by Fidelis CarePolicy N/A

    Oncology Services - Medicare | Oncology medication prior authorization and billing list (Wellcare by Fidelis Care)

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Evolent review/prior authorization requirements and lists HCPCS/HCPCS-like and pharmacy codes for oncology medications and supportive agents for Wellcare by Fidelis Care Medicare members; includes out-of-scope items and preferred biosimilar agents. Applies to dispensing at pharmacy or administration in physician office, outpatient hospital, or ambulatory settings.

    Policy Summary
    PayerFidelis Care | Wellcare by Fidelis Care
    PolicyOncology Services - Medicare | Oncology medication prior authorization and billing list (Wellcare by Fidelis Care)
    Policy CodePolicy N/A
    Change TypeOperational / Effective date noted
    Effective Date6/1/2026
    Next Review DateJun 1, 2026
    Key ActionParticipating providers must submit all oncology medication and supportive agent requests (entire regimen) to Evolent prior to dispensing at pharmacy or administration in office/outpatient/ambulatory settings; non-participating providers submit to plan by fax (1-844-235-5090) effective 10/1/2023.
    SourceLink
    POLICY UPDATE CHANGES

    Effective 6/1/2026 for Wellcare by Fidelis Care - many oral agents listed under J8999 included (policy text indicates effective date for Wellcare by Fidelis Care).

    Non-participating provider fax updated to 1-844-235-5090 (formerly 1-877-882-5892) effective 10/1/2023.

    300+Listed HCPCS/J/Q codes and mappings
    Section A & BCoverage pathways (medical/pharmacy)
    1Evolent prior authorization vendor

    Policy summary

    Wellcare by Fidelis Care requires Evolent review to establish medical necessity for oncology medications and supportive agents prior to dispensing or administration. Coverage pathways are defined in two sections: Section III.A lists drugs that may be billed via either the medical or pharmacy benefit (available via medical or pharmacy benefit) and Section III.B lists drugs that are pharmacy benefit only. The requirement applies when medications are dispensed at a pharmacy or administered in a physician's office, outpatient hospital, or ambulatory setting, and the policy notes preferred biosimilars and a comprehensive HCPCS/J-/Q-code set for drugs that require review; certain services (e.g., antibiotics, bone marrow/stem cell transplants and CAR-T, inpatient drugs, radiopharmaceuticals, equipment requests, genetic testing, immune globulins and others) are explicitly out of scope for Evolent.

    Policy metadata
    PayerFidelis Care / Wellcare by Fidelis Care
    Policy TitleOncology Services - Medicare | Wellcare by Fidelis Care
    Policy NumberN/A
    Effective DateEffective 6/1/2026 (Wellcare by Fidelis Care)
    Policy Summary
    PayerFidelis Care | Wellcare by Fidelis Care
    PolicyOncology Services - Medicare | Oncology medication prior authorization and billing list (Wellcare by Fidelis Care)
    Policy CodePolicy N/A
    Change TypeOperational / Effective date noted
    Effective Date6/1/2026
    Next Review DateJun 1, 2026
    Key ActionParticipating providers must submit all oncology medication and supportive agent requests (entire regimen) to Evolent prior to dispensing at pharmacy or administration in office/outpatient/ambulatory settings; non-participating providers submit to plan by fax (1-844-235-5090) effective 10/1/2023.
    SourceLink
    On This Page
    Policy summaryWhen Evolent review / prior authorization is requiredCodes requiring Evolent review (Section III.A & III.B)What providers must doKey termsDocument changes
    Next Review Date2026-06-01
    StatusCURRENT
    Key ActionSubmit oncology medication regimens to Evolent for prior authorization

    When Evolent review / prior authorization is required

    Codes requiring Evolent review (Section III.A & III.B)

    Drugs requiring Evolent review (medical or pharmacy benefit) - HCPCS/J-codes and others (Section III.A)mixedCovered
    C9293GLUCARPIDASE
    J0185DECITABINE INJ / APREPITANT INJ (listed variants)
    J0207LUSPATERCEPT-AAMT / AMIFOSTINE INJ (listed variants)
    J0208DENOSUMAB PROLIA / SODIUM THIOSULFATE (listed variants)
    J0594BUSULFAN INJ / METHYLPREDNISOLONE ACETATE (listed variants)
    J0641LEVOLEUCOVORIN INJ
    J0642INJ DINUTUXIMAB / LEVOLEUCOVORIN INJ
    J0870IMETELSTAT (RYTELO)
    J0881DARBEPOETIN ALFA NON-ESRD
    J0885EPOETIN ALFA NON-ESRD
    1–10 of 96
    1/10
    Drugs requiring Evolent review (pharmacy benefit only) - Oral and other pharmacy codes (Section III.B)mixedCovered
    J7308AMINOLEVULINIC ACID 20% TOPICAL (pharmacy-listed where applicable)
    J8510BUSULFAN ORAL 2 MG
    J8520CAPECITABINE ORAL
    J8521CAPECITABINE ORAL (alternate)
    J8522CAPECITABINE ORAL 50 MG
    J8560ETOPOSIDE ORAL
    J8611METHOTREXATE (JYLAMVO)
    J8612METHOTREXATE (XATMEP)
    J8700TEMOZOLOMIDE ORAL
    J8705TOPOTECAN ORAL
    1–10 of 12
    1/2

    Codes listed in Section III.A may be billed under either the medical or pharmacy benefit; codes in Section III.B are pharmacy-benefit only. Submit all requests to Evolent for review regardless of formulary status or benefit assignment to establish coverage for a medically accepted indication.

    What providers must do

    Prior Authorization

    Evolent review required prior to dispensing/administration

    Participating providers must submit all oncology medication and supportive agent requests to Evolent for review prior to dispensing or administration. Non‑participating providers must submit requests to the plan via fax: 1-844-235-5090 (new as of 10/1/2023; formerly 1-877-882-5892).

    • Web portal: my.newcenturyhealth.com
    • Phone: 1-888-999-7713, option 1
    • Non‑participating provider fax (effective 10/1/2023): 1-844-235-5090
    Documentation Required

    Submit entire oncology regimen

    Submit the entire oncology regimen for review — include all agents, supportive medications, and scheduling. Omitting components of the regimen may result in a denial. Clinical trials may be submitted to Evolent for review.

    • Clinical trials may be submitted to Evolent for review
    Billing Rule

    Drugs may be billed via medical or pharmacy benefit

    Drugs listed in Section III.A may be billed via either the medical or pharmacy benefit; drugs listed in Section III.B are pharmacy‑only. All requests must be submitted to Evolent for review regardless of formulary status or billing pathway.

    • Section III.A — medical or pharmacy benefit
    • Section III.B — pharmacy only
    Prior Authorization

    Submission channels

    Requests to Evolent can be submitted through the web portal, by phone, or (for non‑participating providers) by fax to the plan. Use the portal or phone for participating‑provider submissions and the fax number shown for non‑participating providers.

    • Portal: my.newcenturyhealth.com
    • Phone: 1-888-999-7713, option 1
    • Non‑participating provider fax (effective 10/1/2023): 1-844-235-5090

    Key terms

    Definitions
    EvolentThird-party utilization review organization that performs prior authorization reviews for oncology medications.
    Participating ProviderProvider participating with the plan network; such providers submit requests to Evolent via portal/phone.

    Document changes

    2026-06-01addedLatest

    Effective 6/1/2026 for Wellcare by Fidelis Care: many oral oncology agents listed under J8999 included; J8999 effective date noted for pharmacy benefit list.

    2023-10-01clarified

    Non-participating provider fax updated to 1-844-235-5090 (formerly 1-877-882-5892) effective 10/1/2023 for submission of requests to the plan.

    noted

    Document contains effective date line present; no specific clinical criteria changes described.